Journal article
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men
E Killick, R Morgan, F Launchbury, E Bancroft, E Page, E Castro, Z Kote-Jarai, A Aprikian, I Blanco, V Clowes, S Domchek, F Douglas, D Eccles, DG Evans, M Harris, J Kirk, J Lam, G Lindeman, G Mitchell, N Pachter Show all
Scientific Reports | NATURE PORTFOLIO | Published : 2013
DOI: 10.1038/srep02059
Abstract
Controversy surrounds the use of PSA as a biomarker for prostate cancer detection, leaving an unmet need for a novel biomarker in this setting; urinary EN2 may identify individuals with clinically relevant prostate cancer. Male BRCA1 and BRCA2 mutation carriers are at increased risk of clinically significant prostate cancer and may benefit from screening. Urine samples from 413BRCA1 and BRCA2 mutation carriers and controls were evaluated. Subjects underwent annual PSA screening with diagnostic biopsy triggered by PSA > 3.0 ng/ml; 21 men were diagnosed with prostate cancer. Urinary EN2 levels were measured by ELISA and had a sensitivity of 66.7% and specificity of 89.3% for cancer detection. ..
View full abstractRelated Projects (1)
Grants
Awarded by NorthShore University HealthSystem
Funding Acknowledgements
We would like to thank the IMPACT study participants and their families. We would also like to thank the IMPACT collaborators from around the world. We are grateful to Tokhir Dadaev for statistical advice. We acknowledge support from the Annabel Evans Memorial Fund, the Ronald & Rita McAulay Foundation, the Prostate Project Charity, Basser Research Centre, Cancer Research UK (grant numbers C5047/A8385 and C5047/A13232) and NIHR. We also acknowledge financial support in Australia for IMPACT from the Cancer Councils of Victoria and South Australia, grant number 400048, the Prostate Cancer Foundation of Australia grant number PCFA PRO4 and Cancer Australia grant number 1006349. We acknowledge funding from Jack and Judy Baker for the study at NorthShore University HealthSystem, Evanston, Illinois, and Myriad Genetics Laboratory, Salt Lake City, Utah, for providing research BRCA testing rates for NorthShore University HealthSystem participants.